Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals

Ann Intern Med. 2017 Feb 7;166(3):219-220. doi: 10.7326/M16-1847. Epub 2016 Dec 13.

Authors

Daniel M Blumenthal¹, Dana P Goldman¹, Anupam B Jena¹

Affiliation

¹ From Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, and Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California.

PMID: 27951598
DOI: 10.7326/M16-1847

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antibodies, Monoclonal / economics
Anticholesteremic Agents / economics
Biopharmaceutics / economics*
Drug Costs*
Humans
Outcome Assessment, Health Care / economics*
PCSK9 Inhibitors
Prescription Fees*
United States

Substances

Antibodies, Monoclonal
Anticholesteremic Agents
PCSK9 Inhibitors
PCSK9 protein, human

Grants and funding